Prince Pharmaceutical Co., Ltd. (TPEX:6935)
Taiwan · Delayed Price · Currency is TWD 28.45
+0.10 (0.35%)
Sep 8, 2026, 1:41 PM CST
Prince Pharmaceutical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,059 | 1,138 | 802 | 1,267 | - | - | |
Market Cap Growth | 7.52% | 42.01% | -36.72% | - | - | - |
Enterprise Value | 1,242 | 1,502 | 1,180 | 1,670 | - | - |
Last Close Price | 28.30 | 30.29 | 21.33 | 33.77 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 8.12 | 11.82 | - | 82.75 | - | - |
PS Ratio | 0.86 | 1.08 | 1.16 | 1.68 | - | - |
PB Ratio | 1.21 | 1.36 | 1.11 | 1.64 | - | - |
P/TBV Ratio | 1.22 | 1.36 | 1.11 | 1.64 | - | - |
P/FCF Ratio | 6.24 | 15.85 | 28.42 | 2827.58 | - | - |
P/OCF Ratio | 5.49 | 12.64 | 17.35 | 20.27 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.01 | 1.42 | 1.71 | 2.22 | - | - |
EV/EBITDA Ratio | 5.85 | 9.18 | 259.75 | 21.99 | - | - |
EV/EBIT Ratio | 8.20 | 13.55 | - | 64.79 | - | - |
EV/FCF Ratio | 7.32 | 20.92 | 41.83 | 3728.36 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.47 | 0.50 | 0.64 | 0.63 | 0.80 | 0.94 |
Debt / EBITDA Ratio | 1.92 | 2.45 | 35.06 | 5.81 | 4.35 | 12.80 |
Debt / FCF Ratio | 2.41 | 5.88 | 16.33 | 1094.55 | 7.25 | 409.55 |
Net Debt / Equity Ratio | 0.21 | 0.32 | 0.50 | 0.48 | 0.69 | 0.82 |
Net Debt / EBITDA Ratio | 0.90 | 1.65 | 78.80 | 4.84 | 3.97 | 12.32 |
Net Debt / FCF Ratio | 1.08 | 3.75 | 12.69 | 820.97 | 6.26 | 357.09 |
Asset Turnover | 0.82 | 0.74 | 0.50 | 0.56 | 0.55 | 0.35 |
Inventory Turnover | 4.00 | 4.78 | 4.34 | 4.11 | 3.68 | 2.79 |
Quick Ratio | 0.93 | 1.13 | 0.94 | 1.09 | 0.76 | 0.67 |
Current Ratio | 1.69 | 1.81 | 1.56 | 1.85 | 1.59 | 1.37 |
Return on Equity (ROE) | 16.14% | 12.34% | -7.16% | 2.14% | 8.18% | -1.37% |
Return on Assets (ROA) | 6.35% | 4.86% | -2.24% | 1.19% | 3.26% | -0.06% |
Return on Invested Capital (ROIC) | 12.72% | 9.32% | -4.44% | 1.83% | 4.93% | -0.10% |
Return on Capital Employed (ROCE) | 12.50% | 9.30% | -4.40% | 2.20% | 6.10% | -0.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 12.29% | 8.46% | -6.68% | 1.21% | - | - |
FCF Yield | 16.03% | 6.31% | 3.52% | 0.03% | - | - |
Dividend Yield | 1.69% | 1.65% | - | 0.74% | - | - |
Payout Ratio | - | - | - | 35.46% | - | - |
Buyback Yield / Dilution | -2.26% | -1.03% | -0.09% | -9.66% | -0.41% | -1.45% |
Total Shareholder Return | -0.57% | 0.62% | -0.09% | -8.92% | -0.41% | -1.45% |